BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX opened at $0.27 on Friday. The business has a 50-day simple moving average of $0.32 and a two-hundred day simple moving average of $0.52. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a 52 week low of $0.19 and a 52 week high of $1.58. The stock has a market cap of $21.89 million, a price-to-earnings ratio of -1.24 and a beta of 1.39.

Institutional Investors Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently bought and sold shares of BLRX. Atria Investments Inc boosted its stake in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the period. PVG Asset Management Corp purchased a new position in BioLineRx in the 2nd quarter worth approximately $70,000. Finally, CVI Holdings LLC bought a new position in BioLineRx in the 2nd quarter worth approximately $462,000. 1.56% of the stock is owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.